US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter inhibitor
pharma · Influenza · Encephalitis, Japanese B
Repatha
Repatha drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
JP HQ
PMDA registrant Type
Company details
- Status
- Public
- HQ
- JP
- Programs
- 3
- Drugs
- 6
- Patents
- 0
Repatha pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Repatha drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Repatha's portfolio.
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Repatha's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Repatha's portfolio.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Repatha in public FDA and regional records.